The Chemotherapy Induced Peripheral Neuropathy drugs in development market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chemotherapy Induced Peripheral Neuropathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued products.
GlobalData tracks 68 drugs in development for Chemotherapy Induced Peripheral Neuropathy by 64 companies/universities/institutes. The top development phase for Chemotherapy Induced Peripheral Neuropathy is preclinical with 37 drugs in that stage. The Chemotherapy Induced Peripheral Neuropathy pipeline has 61 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Chemotherapy Induced Peripheral Neuropathy pipeline products market are: Galleon Bio, Serpin Pharma and Novaremed.
The key targets in the Chemotherapy Induced Peripheral Neuropathy pipeline products market include Histone Deacetylase 6, Cannabinoid Receptor 2, and Sodium Channel Protein Type 9 Subunit Alpha.
The key mechanisms of action in the Chemotherapy Induced Peripheral Neuropathy pipeline product include Histone Deacetylase 6 Inhibitor with six drugs in Phase I. The Chemotherapy Induced Peripheral Neuropathy pipeline products include 13 routes of administration with the top ROA being Oral and ten key molecule types in the Chemotherapy Induced Peripheral Neuropathy pipeline products market including Small Molecule, and Peptide.
Chemotherapy Induced Peripheral Neuropathy overview
Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes, and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy, and type of chemotherapeutic agent.
For a complete picture of Chemotherapy Induced Peripheral Neuropathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
